Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 11/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22787252 | 0.92 | TYMP (0.42) | TYMPTAS1R3TAS1R1NT5EHPGD | |
| SCHEMBL916676 | 0.86 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL24433797 | 0.86 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL24548715 | 0.86 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL25569964 | 0.86 | TYMP (0.42) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL668619 | 0.86 | TYMP (0.45) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL23138150 | 0.86 | TYMP (0.45) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL22960797 | 0.86 | TYMP (0.41) | TYMPTAS1R3TAS1R1KDM4ENT5E | |
| SCHEMBL18787574 | 0.85 | TYMP (0.42) | TYMPADORA3ADORA2BADORA1 | |
| SCHEMBL12513080 | 0.84 | TYMP (0.40) | TYMPTAS1R3TAS1R1KDM4ENT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | TYMP 190/4885TAS1R3 3536/4885TAS1R1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.